The drug’s safety and tolerability profile in the trial was in line with previously reported data. Credit: aslysun / Shutterstock.

UK-based pharmaceutical company GSK has reported updated results from a Phase II study of Jemperli (dostarlimab) for locally advanced mismatch repair deficient (dMMR) rectal cancer.

The drug candidate was found to be 100% effective in treating all patients who were enrolled in the trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The supported collaborative study was conducted in collaboration with Memorial Sloan Kettering Cancer Center.

In the trial, Jemperli was assessed as a first-line therapy that could replace surgery for dMMR locally advanced rectal cancer.

The trial’s findings showed that all 42 patients who completed the treatment with dostarlimab showed a 100% clinical complete response rate (cCR) with no evidence of tumours or complete pathologic response.

A sustained clinical complete response was observed in the first 24 subjects, with a median follow-up of 26.3 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dostarlimab’s safety and tolerability profile aligned with the already reported data without any adverse events of Grade III or higher observed.

Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that is being assessed in various immuno-oncology-based research and development programmes.

The drug is not currently approved for the frontline treatment of locally advanced dMMR rectal cancer anywhere in the world.

GSK is actively pursuing further studies through its AZUR clinical trial programme, focusing on advanced and metastatic stages of dMMR/MSI-H colorectal cancer.

GSK oncology R&D global head and senior vice-president Hesham Abdullah said: “The data showing no evidence of disease in 42 patients is remarkable.

“These results bring us one step closer to understanding the potential of dostarlimab in this curative-intent setting for patients with dMMR locally advanced rectal cancer.

“We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies.”

Last month, GSK announced positive data from two Phase III trials of its asthma candidate depemokimab.